Health Care & Life Sciences » Biotechnology | Bioinvent International AB

Bioinvent International AB | Cash Flow

Fiscal year is January-December. All values SEK Thousands.
2013
2014
2015
2016
2017
2018
Net Income before Extraordinaries
19,176.00
54,925.00
94,973.00
62,859.00
100,632.00
123,232
Depreciation, Depletion & Amortization
2,896.00
2,041.00
1,650.00
996.00
2,880.00
5,061
Other Funds
978.00
704.00
4,554.00
92.00
418.00
356
Funds from Operations
15,302.00
52,180.00
88,769.00
61,771.00
97,334.00
117,815
Changes in Working Capital
39,350.00
23,848.00
16,196.00
10,278.00
21,458.00
23,579
Net Operating Cash Flow
54,652.00
76,028.00
72,573.00
72,049.00
75,876.00
141,394
Capital Expenditures
47.00
414.00
672.00
5,322.00
16,478.00
Net Investing Cash Flow
47.00
414.00
672.00
5,322.00
16,478.00
Net Financing Cash Flow
19,383.00
57,324.00
67,591.00
263,512.00
-
Net Change in Cash
35,316.00
19,118.00
5,654.00
186,141.00
92,354.00
Free Cash Flow
54,699.00
76,442.00
73,245.00
77,371.00
92,354.00
Change in Capital Stock
19,383.00
57,324.00
67,591.00
263,512.00
-

About Bioinvent International AB

View Profile
Address
Sölvegatan 41
Lund SN 223 70
Sweden
Employees -
Website http://www.bioinvent.com
Updated 07/08/2019
BioInvent International AB engages in the research and development of immuno-regulatory antibodies to treat cancer. Its clinical programs include BI-1206 for non-Hodgkin's lymphoma and chronic lymphatic leukaemia; TB-403 for paediatric brain tumors; and THR-317 for diabetic macular edema. Its technology platforms consist of F.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.